TrialClinical and experimental nephrology2018

The renoprotective effect and safety of a DPP-4 inhibitor, sitagliptin, at a small dose in type 2 diabetic patients with a renal dysfunction when changed from other DPP-4 inhibitors: REAL trial.

Koichi Kanozawa et al.PubMed ↗Publisher ↗

No numbers read from the abstract.